Hepatitis C is a contamination that for the most part influences the liver. The hepatitis C infection (HCV) causes this sickness. Frequently, a man with Hepatitis C does not have any indications (medical issues or signs that he has the ailment). In any case, ceaseless contamination can scar the liver. Numerous years of disease may bring about cirrhosis. Infrequently, individuals with cirrhosis additionally have liver disappointment or liver tumor. They can likewise have extremely swollen veins of the throat and stomach. The blood misfortune from this issue can execute.
Hepatitis C is typically spread by blood-to-blood contact (when blood from a man with Hepatitis C contacts (touches or gets into) someone else's circulatory system). The most well-known ways this happens are through intravenous medication utilize (when a man shoots drugs into one of their veins, with a needle that was at that point utilized by a man contaminated with Hepatitis C); nonsterile restorative hardware (therapeutic devices that were not cleaned all around ok in the wake of being utilized on a tainted individual); and blood transfusions (when a man is given blood that originated from a contaminated individual)
Minimum Order Quantity | 1 Bottle |
Composition | SOFOSBUVIR 400 MG & VELPATASVIR 100 MG |
Treatment | HEPATITIS C |
Prescription/Non prescription | Prescription |
Brand | SOVIHEP V |
Manufacturer | Cadila Healthcare Ltd (Zydus) |
Form | Tablet |
Strength/Dose (in mg or ml) | SOFOSBUVIR 400 MG & VELPATASVIR 100 MG |
Pack Size | 28 Tab |
Product Type | Finish Product |
Shelf life | 2021 |
Sofosbuvir With Velpatasvir is a two-drug combination for the treatment of hepatitis C. It is administered as a single daily pill containing the viral NS5A inhibitor velpatasvir and sofosbuvir, a nucleotide inhibitor of the viral RNA polymerase. It is the first treatment, that works for all genotypic, and is taken entirely by mouth. A single tablet regimen is used for adults with genotype 1-6 chronic hepatitis C virus (HCV) infection.
Mechanism of action:Sofosbuvir With Velpatasvir is an oral fixed-dose combination of sofosbuvir, a nucleotide analog NS5B polymerase inhibitor and velapatasvir, an NS5A replication complex inhibitor. Sofosbuvir is approved for the treatment of genotype 1, 2, 3 and 4 HCV infection with different regimens and durations dependent on the HCV genotype. Velpatasvir (formerly GS-5816) is a novel NS5A inhibitor that has potent invitro anti-HCV activity across all genotypes at the picomolar level. The combination of sofosbuvir-velpatasvir is the first once-daily single-tablet regimen with pangenotypic activity.
Dosage and Administration:Sofosbuvir With Velpatasvir is available as a coformulated, once-daily single-pill combination of sofosbuvir 400 mg and velpatasvir 100 mg. The recommended dose is one tablet once daily, taken with or without food.
Risk of Serious Symptomatic Bradycardia When Sofosbuvir Is Coadministered with Amiodarone and Another HCV Direct Acting Antiviral: Amiodarone is not recommended for use with Sofosbuvir With Velpatasvir due to the risk of symptomatic bradycardia, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/or with advanced liver disease. In patients without alternative, viable treatment options, cardiac monitoring is recommended. Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia.
Risk of Reduced Therapeutic Effect Due to Concomitant Use of Sofosbuvir With Velpatasvir with P-gp Inducers and/or Moderate to Potent Inducers of CYP2B6, CYP2C8 or CYP3A4: Rifampin, St. John''''s wort, and carbamazepine are not recommended for use with Sofosbuvir With Velpatasvir as they may significantly decrease sofosbuvir and/or velpatasvir plasma concentrations.
Form | Tablet |
Strength/Dose (in mg or ml) | Sofosbuvir 400 mg & velpatasvir 100 mg |
Pack Size | 28 Tab |
Packaging Size | 28 TABS |
Strength | 400MG/100MG |
Composition | SOFOSBUVIR + VELPATASVIR |
Treatment | HEPATITIS C |
Prescription/Non prescription | Prescription |
Velpatasvir Sofosbuvir ( Tab Velasof ) by Hetero is a combination of sofosbuvir and velpatasvir and is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It is also used with another antiviral medication (ribavirin). These drugs work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover.
Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer.
Sofosbuvir 400 mg Velpatasvir 100 mg Indication :
Velasof ( Sofosbuvir 400 mg velpatasvir 100 mg) is used alone or with ribavirin to treat chronic hepatitis C. Sofosbuvir is in a class of antiviral medications called nucleotide hepatitis C virus (HCV) NS5B polymerase inhibitors. Velpatasvir is in a class of antiviral medications called HCV NS5A replication complex inhibitors.
The combination of sofosbuvir and velpatasvir works by stopping the virus that causes hepatitis C from spreading inside the body.
Prescription/Non prescription | Prescription |
Packaging Size | 30 Tablets |
Dose | 50 MG |
Composition | Dolutegravir 50mg |
Treatment | It is used to treat HIV (human immunodeficiency virus), the virus that can cause AIDS (acquired imm |
Dolutegravir is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults and children 12 years of age and older and weighing at least 88 pounds (40 kilograms). Dolutegravir is always used in combination with other HIV medicines.
Dolutegravir belongs to a class (group) of HIV drugs called integrase inhibitors. Integrase inhibitors block an HIV enzyme called integrase. (An enzyme is a protein that starts or increases the speed of a chemical reaction.) By blocking integrase, integrase inhibitors prevent HIV from multiplying and can reduce the amount of HIV in the body. HIV medicines can’t cure HIV/AIDS, but taking a combination of HIV medicines (called an HIV regimen) every day helps people with HIV live longer, healthier lives. HIV medicines also reduce the risk of HIV transmission
What side effects can dolutegravir cause?
Dolutegravir may cause side effects. Most side effects from dolutegravir are manageable, but a few can be serious. Serious side effects of dolutegravir include allergic reactions and liver problems. (See the WARNING above.)Other possible side effects of dolutegravir include:
Changes in liver test results. People with a history of HBV or HCV may have an increased risk of developing new or worsening changes in certain liver test results during treatment with dolutegravir.
Changes in body fat (including gain or loss of fat).
Immune reconstitution inflammatory syndrome (IRIS), a condition that sometimes occurs when the immune system begins to recover after treatment with an HIV medicine. As the immune system gets stronger, it may have an increased response to a previously hidden infection.
Trouble sleeping.
Tiredness.
Headache.
Tell your health care provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of dolutegravir. To learn more about possible side effects of dolutegravir, read the drug label or package insert or talk to your health care provider or pharmacist.The AIDSinfo fact sheet on HIV Medicines and Side Effects also includes information that may apply to dolutegravir.
30 Tab
*Your information is safe with us.
Composition | SOFOSBUVIR 400 MG AND VELPATASVIR 100 MG |
Uses | HEPATITIS C TREATMENT |
Dosage Form | Tablet |
Packaging Type | BOTTLE |
Form | Tablets |
Brand | VELAKAST |
Packaging Size | 28 |
Pack size | 28 TABLETS,28 TABLETS |
Brand | SOFOKAST DACIKAST |
Manufacturer | APRAZER |
Composition | SOFOSBUVIR DACLATASVIR |
Treatment | HEP C |
Prescription/Non prescription | Prescription |
Form | Tablet |
Daclatasvir 400 mg +Sofosbuvir 90 mg is used in the treatment of chronic hepatitis C virus (HCV) infection.
Pack size | 28 TABLETS |
Brand | HEPCINAT |
Manufacturer | NATCO |
Composition | DACLATASVIR 60MG,SOFOSBUVIR 400MG |
Prescription/Non prescription | Prescription |
Form | Tablet |
*Your information is safe with us.
Strength | 200 MG |
Brand | RIBASURE |
Composition | RIBAVIRIN |
Drug Name | RIBASURE |
Usage/Application | ORAL TABLETS |
Manufactured By | APRAZER |
Pack size | 28 tablets |
Composition | Sofosbuvir 400mg + Velpatasvir 100mg |
Treatment | HEP C |
Prescription/Non prescription | Prescription |
Form | Tablet |
Brand | hepcvel |
Manufacturer | Cipla Ltd |
Packaging Size | 28 |
Strength | 400/100 |
Composition | sofosbuvir + velpatasvir |
Treatment | treatment of chronic hepatitis C virus (HCV) infection |
Prescription/Non prescription | Prescription |
Brand | sofocure v |
Form | Tablet |
*Your information is safe with us.
Pack size | 1*28 TABLETS |
Composition | Sofosbuvir + velpatasvir |
Treatment | Hepatitis c |
Prescription/Non prescription | Prescription |
Brand | VELPACLEAR |
Manufacturer | ABBOTT |
Form | Tablet |
Packaging Size | 28 TABLETS |
Strength | 400MG / 60 MG |
Composition | SOFOSBUVIR + DACLATASVIR |
Treatment | HCV |
Prescription/Non prescription | Prescription |
Brand | APRAZER |
Manufacturer | NATCO |
Form | Tablet |
Country of Origin | Made in India |
Pack size | 28 TAB |
Brand | DACLACURE |
Manufacturer | EMCURE |
Composition | DACLATASVIR 60 MG |
Treatment | HEPATITIS C |
Prescription/Non prescription | Prescription |
Packaging Size | 28 Tablets |
Dose/Strength (ex. 1 mg or 1 ml) | 60 MG |
Other Details: 28 Tablets
*Your information is safe with us.
Pack size | 28 TAB |
Composition | DACLATAVSIR 60 MG |
Treatment | HEPATITIS C |
Prescription/Non prescription | Prescription |
Brand | NATDAC |
Manufacturer | NATCO |
Packaging Size | 28 tablets |
Dose/Strength (ex. 1 mg or 1 ml) | 60 mg |
Usage | Hospital, Clinical |
With our in-depth knowledge and rich industry experience in this field, we are highly engaged in exporting, retailing, wholesaling and supplying a qualitative NATDAC Tablet for our esteemed clients. Processed employing advanced technology and using premium quality chemical compounds, offered tablet should only be used under proper medical guidance and advice. In order to maintain the effectiveness, our quality examiners test this tablet on various parameters.
Features:
Other Details: 28 Tablets.
Brand | SOVIHEP |
Manufacturer | Cadila Healthcare Ltd (Zydus) |
Composition | SOFOSBUVIR 400 MG |
Treatment | HEPATITIS C |
Prescription/Non prescription | Prescription |
Strength/Dose (in mg or ml) | 400 mg |
Pack Size | 28 Tablets |
Product Type | Finish Product |
Pack size | 28 TAB |
Brand | DACIHEP |
Manufacturer | Cadila Healthcare Ltd (Zydus) |
Composition | DACLATASVIR 60 MG |
Packaging Size | 28 Tablets |
Dose/Strength (ex. 1 mg or 1 ml) | 60 mg |
*Your information is safe with us.
Pack size | 28 TAB |
Brand | HEPCINAT |
Manufacturer | NATCO |
Composition | SOFOSBUVIR 400 MG |
Treatment | HEPATITIS C |
Prescription/Non prescription | Prescription |
Other Details: 28 Tablets.
Additional Information:
Strength/Dose (in mg or ml) | 400 mg |
Form | Tablet |
Strength | 400 MG |
Packaging Size | 28 TABLETS |
Composition | Sofosbuvir (400mg) |
Treatment | It is used along with other medications for the treatment of chronic hepatitis C virus (HCV) infect |
Prescription/Non prescription | Prescription |
Pack Size | 28 Tablets |
Product Type | Finish Product |
Composition | SOFOSBUVIR 400 MG |
Treatment | HEPATITIS C |
Prescription/Non prescription | Prescription |
Brand | HEPCVIR |
Manufacturer | Cipla Ltd |
Form | Tablet |
Packaging Size | 30 TAB |
Strength/Dose (in mg or ml) | 400 mg |
Usage/Application | Personal |
Pack Size | 28 Tablets |
Packaging Type | BOTTLE |
Manufactured By | CIPLA |
Other Details: 15 Tablets.
*Your information is safe with us.
Minimum Order Quantity | 1 Bottle |
Pack size | 30 TAB |
Brand | X VIR 0.5 |
Manufacturer | NATCO |
Composition | ENTECAVIR 0.5 |
Treatment | HEPATITIS B |
Prescription/Non prescription | Prescription |
Packaging Size | 30 Tabets |
Dose/Strength (ex. 1 mg or 1 ml) | 0.5 mg |
Product Type | Finish Product |
Treatment | It is used along with other medications for the treatment of chronic hepatitis C virus (HCV) infecti |
Packaging Size | 28 TABLETS |
Prescription/Non prescription | Prescription |
Strength/Dose (in mg or ml) | 400 mg |
Pack Size | 28 Tablets |
Form | Tablet |
Strength | 400 MG |
Composition | Sofosbuvir (400mg) |
Prescription/Non prescription | Prescription |
Strength/Dose (in mg or ml) | 400 mg |
Pack Size | 28 Tablets |
Composition | Ledipasvir (90mg) + Sofosbuvir (400mg) |
Form | Tablet |
Product Type | Finish Product |
Packaging Size | 28 TABLETS |
Strength | 90+400 |
Treatment | Resof-L Tablet is a combination of two antiviral medicines. This prescription medicine is used in th |
*Your information is safe with us.
Pack size | 28 TAB |
Composition | SOFOSBUVIR 400 MG |
Treatment | HEPATITIS C |
Prescription/Non prescription | Prescription |
Brand | SOFOKAST |
Manufacturer | APRAZER |
Form | Tablet |
Shelf life | 2021 |
Pack size | 28 TABS |
Brand | VELPANAT |
Manufacturer | NATCO |
Composition | VELPATASVIR 100MG,SOFOSBUVIR 400MG |
Treatment | HEP C |
Prescription/Non prescription | Prescription |
Form | Tablet |
Pack size | 28 TABLETS |
Composition | Sofosbuvir 400 mg |
Treatment | Hepatitis c |
Prescription/Non prescription | Prescription |
Brand | HEPCIVIR |
Manufacturer | Cipla Ltd |
Form | Tablet |
*Your information is safe with us.
Pack size | 28 TABLETS |
Composition | DACLATASVIR |
Treatment | HEPATITIS C |
Prescription/Non prescription | Prescription |
Brand | HEPCDAC |
Manufacturer | Cipla Ltd |
Form | Tablet |
Pack size | 28 TAB |
Composition | SOFOSBUVIR 400 MG AND LEDIPASVIR 90 MG |
Treatment | HEPATITIS C |
Prescription/Non prescription | Prescription |
Manufacturer | APRAZER |
Dosage Form | Tablet |
Packaging Size | 28 |
Brand | LEDIKAST |
Brand Name LEDIKAST
Contents Ledipasvir and Sofosbuvir
Marketed by Aprazer Health Care
Manufactured by Natco Pharma Limited
Strength - Each film-coated tablet Contains 90 mg Ledipasvir and 400 mg Sofosbuvir
Form Tablets
Packing Pack of 28 Tablet
Each film-coated tablet contains 90 mg ledipasvir and 400 mg sofosbuvir. The tablet includes the following inactive ingredients colloidal silicon dioxide, copovidone, croscarmellose sodium, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. The tablet is film-coated with a coating material containing the following inactive ingredients Yellow Oxide of Iron, polyethylene glycol, polyvinyl alcohol, talc, FD&C Blue #2 and titanium dioxide IP. -
Ledipasvir The IUPAC name for ledipasvir is Methyl [(2S)-1-{(6S)-6-[5-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2azabicyclo[2.2.1] hept-3-yl]-1H-benzimidazol-6-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4] hept-5-yl}-3-methyl-
2.1 Mechanism of Action
Ledikast is a fixed-dose combination of ledipasvir and sofosbuvir which are directacting antiviral agents against the hepatitis C virus.
2.2 Pharmacodynamics
Cardiac Electrophysiology
Ledipasvir at a dose of 120 mg twice daily (2.67 times the maximum recommended dosage) and sofosbuvir 400 mg (maximum recommended dosage) and 1200 mg (three times the maximum recommended dosage) does not prolong QTc in clinical trials -
2.3 Pharmacokinetics
Absorption
The pharmacokinetic properties of ledipasvir, sofosbuvir, and the predominant circulating metabolite GS-331007 have been evaluated in healthy adult subjects and in subjects with chronic hepatitis C. Following oral administration, ledipasvir median peak concentrations were observed 4 to 4.5 hours post-dose. Sofosbuvir was absorbed quickly and the peak median plasma concentration was observed ~0.8 to 1 hour post dose. Median peak plasma concentration of GS-331007 was observed between 3.5 to 4 hours post-dose.
Based on the population pharmacokinetic analysis in HCV-infected subjects, geometric mean steady-state AUC0-24 for ledipasvir (N=2113), sofosbuvir (N=1542), and GS-331007 (N=2113) were 7290, 1320, and 12,000 ng-hr/mL. Steady-state Cmax for ledipasvir, sofosbuvir, and GS-331007 were 323, 618, and 707 ng/mL. Sofosbuvir and GS-331007 AUC0-24 and Cmax were similar in healthy adult subjects and subjects with HCV infection. Relative to healthy subjects (N=191)
Ledipasvir is >99.8% bound to human plasma proteins. After a single 90 mg dose of [14C]-ledipasvir in healthy subjects, the blood to plasma ratio of [14C]-radioactivity ranged between 0.51
Sofosbuvir is approximately 61-65% bound to human plasma proteins and the binding is independent of drug concentration over the range of 1 g/mL to 20 g/mL. Protein binding of GS-331007 was minimal in human plasma. After a single 400 mg dose of [14C]-sofosbuvir in healthy subjects, the blood to plasma ratio of 14C-radioactivity was approximately 0.7.
Pack size | 28 TAB |
Brand | DACLAHEP |
Manufacturer | HETERO |
Composition | DACLATASVIR 60 MG |
Dose | 60 mg |
Packaging Size | 28 tablets |
Other Details: 28 Tablet
*Your information is safe with us.
Composition | SOFOSBUVIR 400 MG AND LEDIPASVIR 90 MG |
Treatment | HEPATITIS C |
Prescription/Non prescription | Prescription |
Brand | HEPCINAT LP |
Manufacturer | NATCO |
Pack Size | 28 Tablets |
Dose/Strength (mg or ml) | 400 mg |
With our in-depth knowledge and rich industry experience in this field, we are highly engaged in exporting, retailing, wholesaling and supplying a qualitative Hepcinat-Lp Tablet for our esteemed clients. Processed employing advanced technology and using premium quality chemical compounds, offered tablet should only be used under proper medical guidance and advice. In order to maintain the effectiveness, our quality examiners test this tablet on various parameters.
Features:
Other Details: 28 Tablets.
Brand | ASTRAGENECA |
Dose/Strength | 20 MG |
Packaging Type | BOX |
PACKING or STRIP | PACKING |
Grade Standard | Medicine Grade |
Usage/Application | Clinical |